Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

NCT06650748 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Early-stage Breast Cancer

Interventions

DRUG: Dalpiciclib
DRUG: Letrozole

Sponsor

Peking University